Targeting of hematopoietic progenitor cells with MR contrast agents.

PURPOSE To label human hematopoietic progenitor cells with various magnetic resonance (MR) imaging contrast agents and to obtain 1.5-T MR images of them. MATERIALS AND METHODS Hematopoietic progenitor cells, labeled with ferumoxides, ferumoxtran, magnetic polysaccharide nanoparticles-transferrin, P7228 liposomes, and gadopentetate dimeglumine liposomes underwent MR imaging with T1- and T2-weighted spin-echo and fast field-echo sequences. Data were analyzed by measuring MR signal intensities and R1 and R2* relaxation rates of labeled cells and nonlabeled control cells. Mean quantitative data for the various contrast agent groups were assessed for significant differences compared with control cells by means of the Scheffe test. As a standard of reference, MR imaging data were compared with electron microscopic and spectrometric data. RESULTS For all contrast agents, intracellular cytoplasm uptake was demonstrated with electron microscopy and was quantified with spectrometry. When compared with nonlabeled control cells, progenitor cells labeled with iron oxides showed significantly (P <.05) increased R2*. Cells labeled with gadopentetate dimeglumine liposomes showed significantly increased R1. Detection thresholds were 5 x 10(5) cells for gadopentetate dimeglumine liposomes and ferumoxtran, 2.5 x 10(5) cells for ferumoxides and P7228 liposomes, and 1 x 10(5) cells for magnetic polysaccharide nanoparticles-transferrin. CONCLUSION Hematopoietic progenitor cells can be labeled with MR contrast agents and can be depicted with a standard 1.5-T MR imager.

[1]  G. Frija,et al.  Superparamagnetic iron oxides as positive MR contrast agents: in vitro and in vivo evidence. , 1993, Magnetic resonance imaging.

[2]  R. Brooks,et al.  On T2‐shortening by strongly magnetized spheres: A partial refocusing model , 2002, Magnetic resonance in medicine.

[3]  J. Cuppen,et al.  RLSQ: T1, T2, and ρ calculations, combining ratios and least squares , 1987 .

[4]  R. Jain,et al.  Intracellular magnetic labeling of lymphocytes for in vivo trafficking studies. , 1998, BioTechniques.

[5]  R. Weissleder,et al.  Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. , 1990, Radiology.

[6]  Peter van Gelderen,et al.  Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells , 2001, Nature Biotechnology.

[7]  R Weissleder,et al.  Magnetically labeled cells can be detected by MR imaging , 1997, Journal of magnetic resonance imaging : JMRI.

[8]  Ralph Weissleder,et al.  Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells , 2000, Nature Biotechnology.

[9]  H. Weinmann,et al.  Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. , 1984, Physiological chemistry and physics and medical NMR.

[10]  J. Northrop,et al.  Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[11]  E. Rummeny,et al.  Iron-oxide-enhanced MR imaging of bone marrow in patients with non-Hodgkin's lymphoma: differentiation between tumor infiltration and hypercellular bone marrow , 2002, European Radiology.

[12]  R Weissleder,et al.  Superparamagnetic iron oxide: pharmacokinetics and toxicity. , 1989, AJR. American journal of roentgenology.

[13]  R S Balaban,et al.  Assessing contrast on MR images. , 1997, Radiology.

[14]  W. Oyen,et al.  Sterically stabilized liposomes labeled with indium-111 to image focal infection. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  W Semmler,et al.  Targeting of ultrasmall superparamagnetic iron oxide (USPIO) particles to tumor cells in Vivo by using transferrin receptor pathways , 1998, Magnetic resonance in medicine.

[16]  R Weissleder,et al.  High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. , 1999, Bioconjugate chemistry.

[17]  C. W. Jung.  Surface properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. , 1995, Magnetic resonance imaging.

[18]  R Weissleder,et al.  The development of in vivo imaging systems to study gene expression. , 1998, Trends in biotechnology.

[19]  R. Weissleder.  Liver MR imaging with iron oxides: toward consensus and clinical practice. , 1994, Radiology.

[20]  P. Felgner,et al.  Cationic liposome-mediated transfection , 1989, Nature.

[21]  R. Brasch,et al.  Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. , 1984, AJR. American journal of roentgenology.

[22]  J. Marshall,et al.  Improved Cationic Lipid Formulations for In Vivo Gene Therapy , 1995, Annals of the New York Academy of Sciences.

[23]  R. Jain,et al.  Imaging of activated natural killer cells in mice by positron emission tomography: preferential uptake in tumors. , 1993, Cancer research.

[24]  Chien Ho,et al.  In Vivo Dynamic MRI Tracking of Rat T‐Cells Labeled with Superparamagnetic Iron‐Oxide Particles , 1995, Magnetic resonance in medicine.

[25]  David M. Bodine,et al.  Bone marrow cells regenerate infarcted myocardium , 2001, Nature.

[26]  R Weissleder,et al.  Improvement of MRI probes to allow efficient detection of gene expression. , 2000, Bioconjugate chemistry.

[27]  P. Alderson,et al.  Biodistribution of radiolabeled lymphocytes. , 1985, Radiology.